title: An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin.
abstract: This case suggests that initiation of HCV therapy immediately after liver transplantation with well-tolerated, all-oral regimens may achieve a virologic cure in HCV-positive recipients, thus preventing post-transplant HCV recurrence and associated disease progression. This strategy may broaden utilization of HCV-positive donor livers, potentially including HCV-negative transplant recipients.
authors.affiliation: Texas Liver Institute San Antonio Texas USA; Department of Transplant Hepatology University of Texas Health Science San Antonio Texas USA.
authors.forename: Fred
authors.initials: F
authors.lastname: Poordad
authors.affiliation: Texas Liver Institute San Antonio Texas USA; Department of Transplant Hepatology University of Texas Health Science San Antonio Texas USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Lawitz
authors.affiliation: Texas Liver Institute San Antonio Texas USA; Department of Transplant Hepatology University of Texas Health Science San Antonio Texas USA.
authors.forename: Julio A
authors.initials: JA
authors.lastname: Gutierrez
authors.affiliation: Department of Transplant Hepatology University of Texas Health Science San Antonio Texas USA.
authors.forename: Juan
authors.initials: J
authors.lastname: Guerrero
authors.affiliation: Department of Transplant Hepatology University of Texas Health Science San Antonio Texas USA.
authors.forename: Kermit
authors.initials: K
authors.lastname: Speeg
authors.affiliation: Bristol-Myers Squibb Research and Development Wallingford Connecticut USA.
authors.forename: Eugene S
authors.initials: ES
authors.lastname: Swenson
keywords: Daclatasvir; hepatitis C; liver transplantation; sofosbuvir